About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

LY2189265

Company: Eli Lilly and Company
Mechanism: Mechanism not yet reported
Route: Route not yet reported
Recruiting trials: 1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details

Recruiting NCT NCT06739122

A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)

Not yet reported Eli Lilly and Company 55 participants Est. completion 2027-12 51 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT00630825

A Study of Dose Titration of LY2189265 in Overweight Participants With Type 2 Diabetes Mellitus

Not yet reported Eli Lilly and Company 262 participants Est. completion 2009-01 34 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT00734474

A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin

Not yet reported, Not yet reported Eli Lilly and Company 1202 participants Est. completion 2012-07 99 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT00791479

Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes

Not yet reported Eli Lilly and Company 167 participants Est. completion 2010-01 46 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01001104

A Study of LY2189265 in Japanese Patients With Type 2 Diabetes

Not yet reported Eli Lilly and Company 145 participants Est. completion 2010-12 6 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01064687

A Study in Participants With Type 2 Diabetes Mellitus

Not yet reported Eli Lilly and Company 978 participants Est. completion 2012-05 89 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01075282

A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)

Not yet reported Eli Lilly and Company 810 participants Est. completion 2012-11 78 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01126580

A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3)

Not yet reported Eli Lilly and Company 807 participants Est. completion 2012-06 91 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01149421

A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes

Not yet reported Eli Lilly and Company 755 participants Est. completion 2012-01 76 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01191268

A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)

Not yet reported Eli Lilly and Company 884 participants Est. completion 2012-09 101 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01215968

A Study to Evaluate the Effect of LY2189265 on the Speed at Which Food and Drink Leaves the Stomach in Patients With Type 2 Diabetes Mellitus

Not yet reported Eli Lilly and Company 38 participants Est. completion 2011-07 1 site Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01250834

LY2189265 and Atorvastatin Interaction Study

Not yet reported Eli Lilly and Company 27 participants Est. completion 2011-03 1 site Stand-alone

Other conditions: Healthy Volunteers
View official trial listing →
Completed NCT NCT01253304

A Single Dose Study of LY2189265 in Subjects With Varying Degrees of Hepatic (Liver) Impairment

Not yet reported Eli Lilly and Company 26 participants Est. completion 2011-11 2 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01300260

Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose

Not yet reported Eli Lilly and Company 32 participants Est. completion 2011-08 1 site Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01301092

A Study to Compare the Concentrations of LY2189265 After Different Methods of Administration to Healthy Volunteers.

Not yet reported Eli Lilly and Company 30 participants Est. completion 2011-08 1 site Stand-alone

Other conditions: Diabetes Mellitus, Type II
View official trial listing →
Completed NCT NCT01324388

A Study of the Effect of LY2189265 on Two Blood Pressure Drugs

Not yet reported Eli Lilly and Company 51 participants Est. completion 2011-08 3 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01394952

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Not yet reported Eli Lilly and Company 9901 participants Est. completion 2018-08-21 300 sites

Cardiovascular diseaseType 2 diabetes
View official trial listing →
Completed NCT NCT01408888

A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes

Not yet reported Eli Lilly and Company 29 participants Est. completion 2012-04 3 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01432938

A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy Participants

Not yet reported Eli Lilly and Company 28 participants Est. completion 2011-12 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT01436201

A Study of the Effect of Dulaglutide on How Body Handles Digoxin in Healthy Participants

Not yet reported Eli Lilly and Company 24 participants Est. completion 2011-11 1 site Added to GLP-1

Type 2 diabetes
View official trial listing →
Completed NCT NCT01458210

A Study of the Effect of Dulaglutide on How the Body Handles Oral Contraceptive in Healthy Female Participants

Not yet reported Eli Lilly and Company 22 participants Est. completion 2012-02 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT01468181

A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus

Not yet reported Eli Lilly and Company 394 participants Est. completion 2013-12 14 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01524770

A Study to Compare the Effect of Giving Dulaglutide Using an Auto-injector Versus a Manual Syringe

Not yet reported Eli Lilly and Company 50 participants Est. completion 2012-06 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT01558271

A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus

Not yet reported Eli Lilly and Company 492 participants Est. completion 2014-05 14 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01584232

A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus

Not yet reported Eli Lilly and Company 361 participants Est. completion 2013-07 15 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01621178

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Not yet reported Eli Lilly and Company 577 participants Est. completion 2016-12 89 sites

Type 2 diabetesChronic kidney disease
View official trial listing →
Completed NCT NCT01624259

A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes

Not yet reported Eli Lilly and Company 599 participants Est. completion 2013-11 57 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01644500

A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus

Not yet reported Eli Lilly and Company 737 participants Est. completion 2014-08 30 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT01648582

A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus

Not yet reported Eli Lilly and Company 774 participants Est. completion 2014-12 30 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT01667900

A Study of Dulaglutide in Chinese Participants

Not yet reported Eli Lilly and Company 58 participants Est. completion 2014-06 1 site

Type 2 diabetes Other conditions: Healthy Volunteers
View official trial listing →
Completed NCT NCT01769378

Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)

Not yet reported Eli Lilly and Company 300 participants Est. completion 2014-12 31 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT02152371

A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes

Not yet reported Eli Lilly and Company 300 participants Est. completion 2015-10 40 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT02597049

A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus

Not yet reported Eli Lilly and Company 424 participants Est. completion 2017-02 41 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT02750410

A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes

Not yet reported Eli Lilly and Company 159 participants Est. completion 2018-06-18 25 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT02963766

A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes

Not yet reported Eli Lilly and Company 154 participants Est. completion 2022-01-12 61 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT02973100

A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy

Not yet reported Eli Lilly and Company 318 participants Est. completion 2017-08-14 66 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT03131687

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus

Not yet reported Eli Lilly and Company 318 participants Est. completion 2018-08-01 49 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT03315780

A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes

Not yet reported Eli Lilly and Company 12 participants Est. completion 2018-02-28 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT03363906

A Study of Dulaglutide in Healthy Participants

Not yet reported Eli Lilly and Company 27 participants Est. completion 2018-06-06 1 site

Other conditions: Healthy
View official trial listing →
Completed NCT NCT03495102

A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes

Not yet reported Eli Lilly and Company 1842 participants Est. completion 2019-10-10 208 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT03861052

A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes

Not yet reported Eli Lilly and Company 636 participants Est. completion 2021-03-31 46 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT04143802

A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)

Not yet reported Eli Lilly and Company 72 participants Est. completion 2020-12-28 4 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT04255433

A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

Not yet reported Eli Lilly and Company 13299 participants Est. completion 2025-06-12 635 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT04515576

A Study of LY3493269 in Participants With Type 2 Diabetes

Not yet reported Eli Lilly and Company 56 participants Est. completion 2021-03-09 3 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT04591626

A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes

Not yet reported Eli Lilly and Company 291 participants Est. completion 2022-04-28 27 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT04641312

A Study of LY3457263 in Healthy Participants and Participants With Type 2 Diabetes

Not yet reported Eli Lilly and Company 67 participants Est. completion 2021-12-21 2 sites Added to GLP-1

Type 2 diabetes Other conditions: Healthy
View official trial listing →
Completed NCT NCT04809220

A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes

Not yet reported Eli Lilly and Company 591 participants Est. completion 2023-04-26 44 sites

Type 2 diabetes Other conditions: Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases, Hypoglycemic Agents
View official trial listing →
Completed NCT NCT05377333

A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes

Not yet reported Eli Lilly and Company 94 participants Est. completion 2023-11-22 5 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT05564039

A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)

Not yet reported Eli Lilly and Company 282 participants Est. completion 2024-08-12 38 sites Added to GLP-1

Type 2 diabetes
View official trial listing →
Completed NCT NCT05659537

A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India

Not yet reported Eli Lilly and Company 212 participants Est. completion 2024-01-16 7 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT07313813

A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus

Not yet reported Eli Lilly and Company 20 participants Est. completion 2026-08-13 1 site Added to GLP-1

Type 2 diabetes
View official trial listing →
Not yet recruiting NCT NCT07668336

A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

Not yet reported Eli Lilly and Company 170 participants Est. completion 2030-03 71 sites

Type 2 diabetes
View official trial listing →

Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

ClinicalTrials.gov — NCT01624259

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.